Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells

Sharon M. Sagnella, Lu Yang, Gemma E. Stubbs, Ebru Boslem, Estefania Martino-Echarri, Katarzyna Smolarczyk, Stacey L. Pattison, Natasha Vanegas, Eva St. Clair, Stephen Clarke, John Boockvar, Jennifer A. MacDiarmid, Himanshu Brahmbhatt

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)


Sagnella et al. report the immune modulatory effects of EnGeneIC Dream Vectors (EDVs), bacterially derived nonviable nanocells bearing cytotoxic payloads, in mouse models and human cancer patients. In addition to cytotoxicity, EDVs induce innate and adaptive immune responses to elicit antitumor effects.

Original languageEnglish
Pages (from-to)354-370.e7
Number of pages24
JournalCancer Cell
Issue number3
Publication statusPublished - 16 Mar 2020
Externally publishedYes


  • cancer
  • combined therapeutic
  • cyto-immunotherapy
  • immunotherapy
  • nanocell
  • PNU-159682
  • supercytotoxin
  • tumor targeting

Cite this